Artichoke Leaf Extract: Digestive Trials and Safety

Key takeaways

  • The main digestive research concerns globe artichoke leaf extracts, not artichoke hearts, Jerusalem artichoke or every product labelled “artichoke”
  • One notable placebo-controlled dyspepsia trial was positive, but it was sponsored by the manufacturer and included a company author
  • Frequently quoted IBS results come from uncontrolled or post-hoc analyses. They do not establish a treatment effect over placebo
  • Evidence that an extract changes bile output or a liver imaging marker does not establish better digestion, SIBO eradication or a “liver detox”
  • Bile-duct obstruction, gallstones, liver disease, Asteraceae allergy and relevant medication use are important reasons to avoid self-treatment

Artichoke leaf extract has preliminary evidence for dyspepsia from a positive manufacturer-sponsored trial; Cochrane rated that single-trial evidence low certainty. The cited IBS studies lack placebo controls, and the small liver studies measure short-term surrogates. Results concern particular preparations and do not establish dependable relief from every retail product, treatment of SIBO or a “liver detox.” Traditional medicinal use and product-specific contraindications remain separate questions (Holtmann trial; Cochrane review; IBS subset; EMA monograph).

Contents

Evidence summary · Identity · Forms · Mechanism · Hype · Benefits · Verdicts · Risks · Interactions · Who should avoid · Studied doses · Laboratory evidence · Funding · Regulation · FAQs · Sources

Evidence summary

The grade applies to the particular claim after funding and formulation checks. Manufacturer-supported studies are described fairly but excluded from the independent benefit basis. Unknown financing or product procurement is not treated as proof of either independence or sponsorship.

ClaimEvidenceSourceFunding/conflictStrength
Relieves functional dyspepsiaPositive six-week randomized trial; one-study Cochrane assessment rated low certaintyHoltmann 2003; Cochrane 2023Lichtwer sponsorship and company authorInsufficient independent evidence
Treats IBSPost-hoc analysis of an uncontrolled postal studyBundy 2004Lichtwer-affiliated coauthor; full budget not resolvedInsufficient
Higher doses work better for indigestionTwo open-label dose groups improved without a difference in primary outcomesMarakis 2002Full funding/procurement unresolved; linked study program had company involvementInsufficient for dose-response or placebo-adjusted benefit
Stimulates bile secretionSmall acute human experiment using direct duodenal administrationKirchhoff 1994Branded preparation; complete funding chain unresolvedLimited physiological evidence
Improves gastric motility as a single ingredientSmall study tested a botanical combinationLazzini 2016Indena employees and funded editorial supportInsufficient for artichoke alone
Treats fatty liver disease Short laboratory/imaging studies; Panahi has allocation and participant-reporting problems Panahi 2018; Holländer 2026 Panahi: Niak and university support. Holländer: no specific grant or financial relationships declared; registry institutional budget, procurement unresolved Insufficient for a broad disease-treatment claim
Eradicates SIBO or repairs the gut lining The studies discussed below do not demonstrate these clinical outcomes Scope of studies below Cell and combination findings cannot establish isolated-extract clinical efficacy Insufficient

What it is

The medicinal material in this review is the leaf of globe artichoke, Cynara cardunculus L., also described as Cynara scolymus. EMA distinguishes dried or powdered leaf from solvent-derived extracts. The identity of the plant part is important: an edible flower bud, purified fiber, leaf powder and an aqueous leaf extract are different interventions. EMA identity and preparations

The question is whether a defined swallowed preparation improves a meaningful digestive outcome compared with a suitable control. It is not whether the plant contains biologically active compounds. Many plants do; that fact alone cannot settle clinical effectiveness.

Jerusalem artichoke is a different ingredient source. A registry describing Jerusalem-artichoke inulin and bowel function should not be counted as a trial of globe-artichoke leaf extract. Nor should a leaf-extract capsule inherit the evidence for isolated inulin simply because the whole plant can contain carbohydrates. Separate Jerusalem-artichoke inulin study record

Forms and grades

PreparationDefining featureWhy it matters
Dried or powdered leafWhole medicinal leaf materialMilligrams cannot be equated to concentrated extract
Dry aqueous leaf extractWater-soluble constituents concentrated from leafExtraction ratio and actual extract amount are relevant
Hydroalcoholic or soft extractDifferent solvent and processingChemistry can differ from the pivotal trial preparation
Extract standardized to phenolics, cynarin or related markersA specification measures selected compounds“As cynarin” may describe an analytical expression, not pure cynarin content
Multi-ingredient digestive formulaArtichoke combined with other active substancesAny result initially belongs to the complete formula
Artichoke food, juice or purified inulinDifferent plant material and compositionNo automatic transfer of extract efficacy

A drug–extract ratio describes the amount of starting plant used relative to extract obtained. It does not guarantee bioequivalence, potency in a patient or a linear conversion between brands. For example, the current German Hepar-SL 320 mg information identifies a water extract with a 4–6:1 ratio. That specification is more useful than a large “equivalent herb” number, but still does not prove that another brand matches the trial. Current product specification

The newer SteatoChoke paper describes standardization as total polyphenols expressed as cynarine. That should not be silently rewritten as a dose of chemically pure cynarin. Extraction method, plant part, analytical method and coingredients all belong in a credible comparison. Holländer formulation description

How it works

Proposed actions include altered bile secretion, smooth-muscle effects and activity of phenolic constituents. These are hypotheses about how an effect might occur. They are not interchangeable with proof of symptom relief.

In a 20-person crossover pilot, a branded extract was placed directly into the duodenum and bile secretion was measured over hours. Some time points favored active treatment. This is human physiology, but the administration route bypassed normal swallowing and the study did not establish sustained relief of IBS, constipation or dyspepsia from ordinary capsules. Kirchhoff 1994

Bile is involved in digestion, but more secretion is not automatically better for every person. An intervention proposed to influence bile flow is particularly unsuitable for casual experimentation when a duct is obstructed or gallstones are present. EMA's restrictions reflect this important boundary. EMA assessment

Hype versus evidence

Artichoke is marketed for fullness, bloating, fat digestion and liver support. A current manufacturer also promotes rapid activation of digestion and effects on the intestinal flora. Those are commercial claims to investigate, not independent evidence. Hepar-SL marketing

Three common leaps are not justified:

  • A bile-secretion experiment does not show that the ordinary cause of bloating is inadequate bile
  • A favorable dyspepsia score does not establish eradication of a bacterial overgrowth syndrome
  • Lower liver fat on an imaging test does not show “detoxification,” prevention of cirrhosis or better long-term clinical outcomes

Dyspepsia can have several causes. Persistent symptoms should not be assigned to low bile, poor motility or a damaged gut lining solely because a supplement is advertised for those explanations. NIDDK explanation of indigestion

Benefits by claim

Functional dyspepsia Insufficient independent evidence

Holtmann’s study recruited 247 adults, with 244 included in analysis. A defined extract at 640 mg three times daily was compared with placebo for six weeks. The summed weekly symptom-improvement score favored extract, 8.3 versus 6.7; quality of life also improved more. These are scale measurements, not percentages cured. Lichtwer Pharma sponsored the trial, and a coauthor had a Lichtwer affiliation (Holtmann 2003).

Cochrane’s 2023 review found low-certainty evidence of a small improvement in global dyspepsia symptoms from the single artichoke trial: SMD −0.34 (95% CI −0.59 to −0.09). Unclear selective-reporting risk and imprecision limited confidence. The reviewers reported university support, no external support and no known conflicts; one Cochrane editor-author did not participate in editing this manuscript. Those review-level disclosures do not change the underlying trial’s Lichtwer sponsorship (Cochrane results, study characteristics and disclosures).

Marakis' open postal study recruited 516 people with self-reported dyspepsia; 454 completed it. Both 320 mg/day and 640 mg/day groups improved over two months, without a difference between groups on primary measures. There was no placebo group. Randomizing the dose does not solve the absence of a no-extract comparison. Marakis 2002

Together, these findings justify further investigation. They do not establish a predictable independent benefit from any retail artichoke extract or show that doubling a dose improves the principal digestive outcome.

Irritable bowel syndrome Insufficient

The 2004 result was a post-hoc subgroup of the earlier postal study: 208 participants were identified as having IBS alongside dyspepsia. The authors reported improvements in symptoms, bowel pattern and quality of life. The reported fall in “IBS incidence” was a before-and-after finding, not a placebo-adjusted cure rate or evidence of disease prevention. A coauthor was affiliated with Lichtwer Pharma UK (Bundy 2004).

Walker’s earlier report analyzed 279 people with IBS-like symptoms from 553 patients in German outpatient practice. The authors could not establish how many met a full IBS diagnosis because the original forms lacked all diagnostic criteria. Symptom scores improved over six weeks, but there was no control group, and a coauthor was affiliated with Lichtwer Pharma UK. This German cohort and the later postal-study subgroup are distinct uncontrolled reports, not independent placebo-controlled confirmations (Walker 2001; Bundy 2004).

Gastric emptying, constipation and SIBO Insufficient for the isolated extract

Lazzini’s crossover pilot studied 11 healthy volunteers given artichoke leaf extract plus ginger. The post-meal ultrasound measure was gastric area at one hour, not relief of a diagnosed digestive disorder or a measurement of the migrating motor complex. It did not isolate artichoke’s contribution. Indena employees were authors, and the company funded editorial assistance; the simultaneous no-conflicts declaration does not negate those relationships (Lazzini 2016).

Neither that physiological experiment nor an uncontrolled report of changed bowel habits establishes treatment of chronic constipation or eradication of SIBO. Faster emptying, a bowel movement, less bloating and microbiological eradication are different outcomes. Adequate trials would need the correct diagnosis, a suitable comparator, prespecified clinical outcomes and follow-up.

Panahi’s eight-week study compared 600 mg/day Cynarol artichoke extract with placebo in people with ultrasound-diagnosed fatty liver. Although described as randomized, its Methods say assignment alternated between groups; the analysis was per protocol, with substantial baseline biochemical imbalances. Participant totals conflict across the abstract, main text, tables and flow diagram. The paper reports favorable laboratory and ultrasound changes, but these reporting and design problems weaken interpretation, and no long-term liver outcome was established. Niak Pharmaceuticals and Baqiyatallah University supported the study despite its no-competing-interests declaration (Panahi original paper).

The SteatoChoke pilot studied 40 bariatric-surgery candidates, with 20 per group, for six weeks. The liver-fat imaging marker CAP was lower with extract at three and six weeks; ultrasound lobe-diameter differences depended on the lobe and time point. Both groups introduced a restrictive preoperative diet for the final three weeks. AST was higher with extract than placebo at six weeks, whereas ALT’s between-group comparisons were nonsignificant; a laboratory change does not establish clinical liver injury. The trial was single-blind and registered retrospectively. The final paper declares no specific grant and no commercial or financial relationships; the registry reports an institutional budget. Product purchase or donation terms remain unknown. This small exploratory surrogate study does not establish treatment of liver disease or ordinary digestive symptoms (Holländer original methods, results and declarations; primary abstract; trial registry).

Research conducted under medical supervision does not cancel contraindications on medicines intended for self-care. The EMA digestive-use monograph lists liver and biliary disorders requiring professional assessment. EMA monograph

What works and what does not

ClaimVerdictNotes
Defined leaf extract may relieve functional dyspepsiaPreliminary signalPivotal evidence commercially sponsored
Established independent IBS treatmentNot establishedUncontrolled and post-hoc studies cannot quantify treatment effect
Corrects a proven general bile deficiencyUnsupported generalizationBile physiology is not a diagnosis
Treats SIBO or restores the migrating motor complexNot established hereNo directly applicable eligible clinical demonstration
Dissolves gallstones or safely clears an obstructionUnsupported and unsafe as self-treatmentBiliary restrictions are central safety information
Prevents liver complicationsNot establishedShort surrogate studies cannot answer this
Any standardized artichoke product is interchangeableUnsupportedPlant part, solvent, extract ratio and chemical specification vary

Risks and side effects

AspectFindingSource
Digestive intoleranceDiarrhea with cramps, upper abdominal discomfort, nausea and heartburn are reportedCurrent Hepar-SL information
FrequencyCurrent product information and EMA describe frequencies as unknownProduct information; EMA public summary
AllergyArtichoke or Asteraceae hypersensitivity is a contraindicationEMA monograph
Biliary and liver disordersObstruction, cholangitis, gallstones and other listed conditions preclude casual self-treatmentEMA assessment
Pregnancy, lactation and childrenAdequate safety data are lacking; product restrictions applyCurrent label
ExcipientsThe examined 320 mg medicine contains lactoseProduct specification

The small studies do not establish rare-event incidence or indefinite safety. A statement that no events occurred in a short trial is not evidence that harm is impossible.

Safety: Severe or persistent abdominal pain, fever or jaundice can signal a condition requiring urgent assessment, including a gallstone complication. Breathing difficulty or swelling of the tongue or throat requires emergency care. Vomiting blood or black, tarry stools requires urgent medical assessment. Persistent vomiting or worsening swallowing difficulty also needs prompt assessment rather than another digestive supplement (NHS gallstone warnings; NHS anaphylaxis guidance; NIDDK alarm symptoms).

Interactions and evidence gaps

Substance or conditionMechanism or concernSeverity/statusSource
Warfarin or phenprocoumonThe examined German medicine warns that anticoagulant effectiveness may be reducedProduct-label warning; magnitude and mechanism are not established by a trial hereHepar-SL professional information
Gallstones, bile-duct obstruction or cholangitisProposed bile stimulation does not treat mechanical obstructionImportant contraindication/suitability issueEMA monograph
Other prescription medicinesDedicated clinical interaction evidence is incompleteAbsence of a report is not demonstrated compatibilityEMA monograph
RosuvastatinAn interaction experiment considered by EMA involved ratsPreclinical only; does not establish a human dose adjustmentEMA 2025 addendum
Multi-herb digestive productsOther active ingredients can introduce separate adverse effects or interactionsProduct-specific review requiredCombination-study example

There is a meaningful source difference: EMA's adopted monograph says interactions were not reported, whereas the current Hepar-SL professional document includes the coumarin warning. Neither should be hidden. The prudent conclusion is to check the actual product with the prescriber or pharmacist, rather than declare every extract safe or assume an identical interaction for every preparation. Anticoagulant doses should not be adjusted on the basis of this article.

This table is selective. It does not certify compatibility with diabetes medicines, immunosuppressants, cancer treatment or every other medicine. Speculation from cell or animal experiments should not be presented as a confirmed human interaction.

Who should avoid self-treatment

People with biliary obstruction, cholangitis, gallstones, liver disease or known artichoke/Asteraceae allergy should follow the relevant contraindications and seek medical advice. Those using coumarin anticoagulants need a medication review. The medicine reviewed here is not intended for children under 12 and advises against use in pregnancy or breastfeeding because of insufficient study. These restrictions concern medicinal preparations; they should not be casually converted into a universal ban on ordinary foods. EMA monograph, product information

Undiagnosed, recurrent or progressive symptoms deserve assessment rather than a presumed supplement deficiency. Research-dose tables do not replace that decision.

Dosage and how it was taken in research

These quantities describe experiments, not a recommended regimen or interchangeable brand equivalents.

Use caseStudied exposureDurationNotes
Functional dyspepsiaTwo 320 mg extract units three times daily, 1,920 mg/day6 weeksManufacturer-sponsored trial; Holtmann
Self-reported mild dyspepsia320 or 640 mg/day2 monthsOpen postal study; no placebo; Marakis
Bile-secretion physiology1.92 g directly into the duodenumSingle experimental administrationNot an oral home-use protocol; Kirchhoff
Fatty-liver laboratory/imaging study 600 mg/day Cynarol 8 weeks Niak and university support; alternating assignment and inconsistent participant reporting (Panahi)
Prebariatric liver imaging 2,600 mg/day specified extract 6 weeks Final three weeks also included a restrictive diet; small surrogate study (Holländer)

These doses answer different formulation-specific research questions; they do not define a safe “effective range.” Historical trial directions may differ from a current medicine’s label. For example, the March 2024 Hepar-SL 320 mg document specifies two capsules twice daily with main meals, whereas Holtmann’s trial used two 320 mg units three times daily. Neither establishes interchangeability with another product (current Hepar-SL directions; historical trial).

Animal and in vitro evidence excluded from benefit conclusions

A Spanish publicly supported study tested artichoke processing-waste extracts in cultured Caco-2 cells and measured responses to oxidative stress. It did not measure clinical gut-barrier repair in people taking leaf capsules. The authors declared no conflicts and listed Spanish national/regional, European and research-network support; those disclosures do not turn cell outcomes into patient benefits (original cell study and funding disclosures).

EMA's 2025 review also discusses rodent liver and drug-interaction experiments. These cannot establish a safe human statin combination, clinical liver protection or a digestive treatment effect. This article's benefit grades do not rely on animal or cell outcomes. EMA addendum

Independent funding tracing

Follow the money

Research funding at a glance

Funding & backersSource & studyClaim & limits

32 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.

No single explicit tier could be mapped. This graphic does not assign a new tier or infer independence.

Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

Who supported the key studies

Lichtwer sponsored the pivotal dyspepsia trial, and a coauthor had a Lichtwer affiliation. The IBS reports also include a Lichtwer UK-affiliated coauthor, although Walker’s patients were in Germany. Lazzini’s combination study names Indena employees and company-funded editorial assistance. Panahi discloses pharmaceutical and university support. SteatoChoke declares no specific grant or financial relationships, with institutional funding in its registry; its procurement terms remain unknown. These are separate financial relationships, not interchangeable “academic” or “independent” labels (Holtmann; Cochrane sponsor extraction; Walker; Bundy; Lazzini; Panahi; SteatoChoke declarations; registry).

The exclusion rule is symmetrical. Industry-supported positive results do not establish independent benefit; an industry-supported null result would not establish independent lack of benefit either. Buying an off-the-shelf ingredient at arm's length is not sponsorship. Unknown payment terms remain unknown.

Ownership, countries and documented backers

Lichtwer Pharma AG was a German company in the pivotal trial; the UK papers identify a UK affiliate. The investor 3i's 2004 annual report records an investment in the herbal-medicine business. A transaction adviser reports that 3i, Clarat Partners and management sold Lichtwer Healthcare's brand portfolio and pharmaceutical rights to MCM Klosterfrau in June 2006. This establishes a historical transaction, not today's shareholder percentages or who financed a 2003 trial. 3i 2004 report, adviser's transaction record

Klosterfrau's current site places Hepar-SL in its portfolio and describes central headquarters functions in Cologne, Germany. Its brand page dates the product's group membership to 2005, while the adviser's wider rights-transaction entry is dated 2006. Those may refer to different steps, but the exact reconciliation was not established. Cassella-med is named in the current medicine information. No current ownership percentage is inferred from these records. Current brand, group structure, medicine document

The Wilhelm Doerenkamp Foundation's own grant site documents its historical connection to preserving the Klosterfrau business and supporting research. That does not by itself establish the complete current legal ownership chain or an artichoke-trial grant. Its charitable purpose does not remove the commercial interests of a medicine business. Foundation's account

Indena’s own history identifies IdB Holding as its parent and describes the Della Beffa family’s involvement. An Indena governance model also describes parent-company control and management/coordination. These are primary corporate self-disclosures, not a complete current beneficial-ownership audit. Exact ultimate stakes were not verified, and a supplier’s corporate identity does not validate its proprietary combination clinically (Indena history; Indena governance model).

Niak’s own contact page identifies a factory near Gorgan, Iran; that is not proof that all headquarters functions are based there. Its history describes an original group of professional investors. Current individual stakes and ultimate control were not established (company factory location; company history).

Documented financial relationships

Linked relationships:

  • Lichtwer’s German business sponsored the dyspepsia trial. Lichtwer UK was represented in IBS-report authorship; Walker’s 279-person patient cohort was German (dyspepsia trial; Walker; Bundy).
  • 3i documented a 2004 investment; a transaction adviser describes the later brand-rights sale by 3i, Clarat and management to Klosterfrau (3i report; June 2006 transaction).
  • Hepar-SL appears in Klosterfrau’s current portfolio. The Doerenkamp Foundation’s historical business link is documented, while exact current ownership stakes remain unverified (brand portfolio; foundation history).
  • Indena’s corporate records identify Italy’s IdB Holding as its parent; Indena employees and funded editorial assistance appear in the artichoke-plus-ginger study (corporate history; governance model; combination-study disclosures).
  • Niak Pharmaceuticals and Baqiyatallah University supported the Panahi liver study (original funding acknowledgment).
  • The SteatoChoke registry names a Saarland institutional budget. The paper declares no specific grant or financial relationships; product procurement terms remain unknown (registry funding; paper declarations).

The core digestive publications discussed here come from German and UK research programs linked to a small number of commercial preparations. Multiple papers or brand names do not automatically provide independent replication. Patient recruitment location, extract manufacture and company headquarters are distinct facts; nationality itself is not a credibility grade.

Regulatory status

European Union and national medicines

EMA recognizes specified artichoke-leaf preparations for traditional relief of digestive complaints, including fullness, bloating and flatulence. Its assessment did not establish a well-established-use indication from adequate clinical evidence. This is a traditional-use framework, with national authorities responsible for individual products. EMA public explanation, assessment conclusion

EMA adopted an addendum in January 2025 reviewing newer information. A periodic review does not constitute authorization for SIBO, liver detoxification or every marketed preparation. 2025 addendum

United States

A dietary supplement's presence on the market is not FDA preapproval of safety and effectiveness. Treatment claims should not be inferred from a supplement label or a study on a differently regulated foreign medicine. FDA supplement guidance

Frequently asked questions

Does artichoke extract help bloating?

The cited dyspepsia trial provides a preliminary symptom signal, rated low certainty by Cochrane, with manufacturer sponsorship. It does not establish a dependable benefit for every person with bloating. Bloating has several possible causes (Cochrane assessment; NIDDK causes).

Does it treat SIBO or improve the migrating motor complex?

The evidence discussed here does not establish either claim for isolated artichoke leaf extract. Lazzini’s small artichoke-plus-ginger study measured post-meal ultrasound gastric area in healthy people, not SIBO eradication or the migrating motor complex (original combination pilot).

Is the 26.4% IBS figure a cure rate?

No. It was a relative before-and-after reduction in reported IBS incidence within a post-hoc subset, without a placebo comparison. It is not the probability that a consumer will be cured (Bundy original abstract).

Is more bile always helpful?

No. Bile-related symptoms need an appropriate diagnosis; the EMA monograph contraindicates the listed medicinal preparations in gallstones, obstruction and other specified liver or biliary disorders (EMA contraindications).

Is “standardized to cynarin” enough to match a study?

No. Plant part, solvent, extract ratio, analytical definition, actual extract dose and other ingredients matter. In SteatoChoke, the specification was total polyphenols expressed as cynarine; it should not be rewritten as a dose of chemically pure cynarin (original formulation description; different product specification).

Why include a positive study but give an insufficient grade?

The result and its financing are separate questions. A manufacturer-sponsored trial can be informative without being an independent replication. Here, Cochrane also rated the single dyspepsia trial low certainty because of unclear selective-reporting risk and imprecision; the IBS reports lack placebo controls (Cochrane; Walker; Bundy).

Sources and funding notes

The tiers describe the financial relationships identified in the records reviewed here: 1, no relevant stake disclosed or identified in those records; 2, indirect ties; 3, an interested party; 4, direct commercial production/support; U, unresolved provenance. They are provisional editorial labels, not a complete funding-chain or ownership certificate. Credibility A–D is assessed separately. Corporate documents and regulated labels can verify their own facts while retaining commercial provenance.

SourceFunding, ownership and countryTier / credibilityAccuracy incentive and remaining gap
Holtmann 2003Germany; Lichtwer sponsorship and author; contract-research authors also present4 / CControlled design and accountable report; direct commercial stake
Cochrane 2023 Researcher support from Chilean and German universities; no external support and no known conflicts declared 1 / B, provisional review-level assessment Transparent review process; editor-author recused from manuscript editing. Underlying Lichtwer-sponsored trial remains separate.
Marakis 2002UK university program; full budget/procurement unresolved; related reports have Lichtwer tiesU / B provisionalPublished methods; no placebo and missing funding detail
Bundy 2004UK; Lichtwer-affiliated coauthor; full financing not established from primary accessible record4 / CResearch reputation; post-hoc uncontrolled subgroup
Walker 2001 German patient cohort; UK/German authors, including Lichtwer UK coauthor; trial cash and supply terms unreported 4 / C Surveillance subgroup lacks complete IBS diagnostic criteria and a placebo control.
Kirchhoff 1994Germany; branded Hepar-SL study; sponsor and procurement terms unresolvedU / B provisionalObjective acute measurement; route and outcome do not establish oral symptom benefit
Lazzini 2016 Italy; Indena employee authors and company-funded editorial assistance, alongside a no-conflicts declaration 4 / C Eleven healthy participants, artichoke plus ginger, one-hour ultrasound outcome; separate trial cash/procurement terms unclear.
Panahi 2018 Niak Pharmaceuticals and Baqiyatallah University supported the study; no competing interests declared 4 / C Alternating assignment, baseline imbalances, per-protocol analysis and conflicting participant totals weaken the short surrogate findings.
Holländer 2026 original paper; primary abstract German academic investigators; no specific grant or commercial/financial relationships declared. Registry institutional budget; procurement terms unknown U / B, provisional procurement assessment Small single-blind pilot, retrospective registration, diet cointervention and surrogate outcomes. Indexed pertinent original sections read; full PDF/supplements unavailable.
SteatoChoke registryInvestigator-entered university record, Germany; institutional budget/no external funds statedU / B provisional for sponsor declarationTime-stamped public record; host does not independently audit every entry
Jerusalem-artichoke inulin registryJapan; Melodian listed as funder and investigator organization, IMEQRD as sponsor; sponsor-entered UMIN record4 / C for provenance, used for identity onlyDefines a different intervention; not used as benefit evidence
Caco-2 laboratory study Spanish national/regional, European and research-network support; no competing interests declared 1 / B, provisional disclosed-funding assessment Waste-derived extracts and cell oxidative-stress responses; not clinical gut-barrier efficacy. Ultimate funding/procurement not fully traced.
EMA overview EU medicines agency; official regulatory source 2 / A for regulatory scope Traditional-use and preparation-specific assessment, not independent replication or a trial-finance audit.
EMA public summarySame EU institution2 / APublic explanation; preparation-specific and traditional-use limits
EMA monographSame EU institution2 / AAdopted regulatory text; missing interaction reports do not prove compatibility
EMA assessmentSame EU institution2 / A for assessment scopeLiterature review; some underlying studies are commercially linked
EMA 2025 addendumSame EU institution2 / ADated update; preclinical findings remain preclinical
Hepar-SL professional informationCassella-med, Germany; manufacturer-origin regulated medicine document4 / CLabel accountability; used for formulation, warnings and regulatory identity
Hepar-SL marketingCommercial German brand website4 / DSales incentive; claims described, not accepted as independent evidence
NIDDK indigestion guidanceUS federal NIH institute1 / A for health guidancePublic accountability; no artichoke efficacy estimate
NHS gallstonesUK publicly funded health service1 / AClinical safety guidance; individual diagnosis still needed
NHS anaphylaxisUK public health service1 / AEmergency guidance; not an ingredient-specific incidence estimate
FDA supplement guidance US federal regulator; official dietary-supplement guidance 2 / A for legal scope Statutory responsibilities and premarket-approval limits; not a clinical benefit endorsement or agency-finance audit.
3i 2004 reportUK investment company, interested primary financial record4 / CFiling accountability; historical holding does not establish current ownership
Ferber transaction recordGerman transaction adviser; fee-based advisory business3 / CPublic deal attribution; exact stakes/brand transfer chronology incomplete
Klosterfrau brand pageCommercial group, Germany4 / C for portfolio, D for promotionBrand identity; its 2005 date differs from the wider 2006 transaction record
Klosterfrau structureGroup self-disclosure; central headquarters Cologne, Germany4 / CCorporate accountability; ultimate ownership not fully traced
Doerenkamp Foundation accountSwiss foundation/grant program with historical business link3 / CPublic mission statement; not a current cap table or trial-funding record
Indena historyItalian supplier; IdB parent and family history self-disclosed4 / CCorporate identity; ultimate percentages not verified
Niak factory location Iranian medicine company; own contact disclosure identifies a factory near Gorgan 4 / C Factory address does not establish the complete headquarters location or clinical efficacy.
Niak historyIranian company; historical investor-group self-description4 / CCorporate accountability; current stakes unknown
Indena governance model Italian commercial group; company model describes IdB parent control 4 / C Relevant original indexed corporate passage only; full current beneficial stakes and clinical funding remain unverified.

Scope: digestive claims and relevant liver/biliary safety context. This is not a complete cardiovascular, liver-treatment or product-market review. Some original papers, procurement terms and ultimate ownership records remain unavailable or unreported; those limits are retained rather than treated as proof of independence.

Have a question — or want us to cover something?

Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.

We store your topic, message, optional email, and this page so we can manage and reply to the request. Do not include diagnoses, medications, or other sensitive medical information. See our Privacy Policy.